Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Oct 1, 2021
Together toward a broader European plasma donation ecosystem
Strengthening the EU Blood Directive: To meet the needs of patients using plasma-derived medicinal products and plasma donors
All
Advocacy
https://cdn.prod.website-files.com/638f893112c6eac0e46ac576/6453f652d7ca1569557512dc_PPTA%20Position%20Paper%20on%20the%20EU%20BTC%20revision_September2021.pdf
Oct 1, 2021
Together toward a broader European plasma donation ecosystem
Strengthening the EU Blood Directive: To meet the needs of patients using plasma-derived medicinal products and plasma donors
All
Advocacy
https://cdn.prod.website-files.com/638f893112c6eac0e46ac576/6453f652d7ca1569557512dc_PPTA%20Position%20Paper%20on%20the%20EU%20BTC%20revision_September2021.pdf
Oct 1, 2021
Plasmavigilance-Adverse events among US Source plasma donors
Source plasma (SP) is the primary starting material for 87% of plasma-derived medicinal products globally. Plasmavigilance is a program designed to collect, analyze, and monitor donor adverse events (AEs) across the SP collection industry.
All
Publication
https://pubmed.ncbi.nlm.nih.gov/34390267/
Oct 1, 2021
Plasmavigilance-Adverse events among US Source plasma donors
Source plasma (SP) is the primary starting material for 87% of plasma-derived medicinal products globally. Plasmavigilance is a program designed to collect, analyze, and monitor donor adverse events (AEs) across the SP collection industry.
All
Publication
https://pubmed.ncbi.nlm.nih.gov/34390267/
Sep 23, 2021
Plasma donations remain disappointingly low through ongoing pandemic, risking patients’ lives
The Plasma Protein Therapeutics Association (PPTA) is aware of emerging reports regarding patients not having reliable access to lifesaving plasma-derived therapies used to treat a variety of serious, rare, and chronic conditions caused by missing or deficient proteins in their blood.
All
PPTA statements
Sep 23, 2021
Plasma donations remain disappointingly low through ongoing pandemic, risking patients’ lives
The Plasma Protein Therapeutics Association (PPTA) is aware of emerging reports regarding patients not having reliable access to lifesaving plasma-derived therapies used to treat a variety of serious, rare, and chronic conditions caused by missing or deficient proteins in their blood.
All
PPTA statements
Sep 1, 2021
The Source Fall 2021
Magazine of the plasma protein therapeutics industry - Fall 2021
All
The Source Magazine
https://drive.google.com/file/d/18ZMDuw0MnmyjHMdEOtrm6hWU9lt5JRMF/view?usp=sharing
Sep 1, 2021
The Source Fall 2021
Magazine of the plasma protein therapeutics industry - Fall 2021
All
The Source Magazine
https://drive.google.com/file/d/18ZMDuw0MnmyjHMdEOtrm6hWU9lt5JRMF/view?usp=sharing
No results found